A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma
Public ClinicalTrials.gov record NCT00843050. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether P276-00 is safe and effective in treatment of Mantle Cell Lymphoma that is recurred after or not responding to at least one previous line of treatment.
Study identification
- NCT ID
- NCT00843050
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 13 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2009
- Primary completion
- Jan 31, 2011
- Completion
- Jul 31, 2012
- Last update posted
- Jul 26, 2012
2009 – 2012
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona | Phoenix | Arizona | 85054 | — |
| Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Arizona | Scottsdale | Arizona | 85259 | — |
| College of Medicine, Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Gabrail Cancer Center Research | Dover | Ohio | 44622 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-5505 | — |
| Cancer Care Centers of South Texas | New Braunfels | Texas | 78130 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78229 | — |
| Huntsman Cancer Institute, 2000 Circle of Hope, Room 2145 | Salt Lake City | Utah | 84112 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Department of Medicine, University of Washington | Seattle | Washington | 98195 | — |
| Dept of Hematology/Oncology, University of Wisconsin- Madison | Madison | Wisconsin | 53792-5156 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00843050, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2012 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00843050 live on ClinicalTrials.gov.